MindRhythm

Executive Summary

MindRhythm is a San Francisco-based medical technology company advancing neurodiagnostics through a real-time detection and monitoring platform for neurological injuries such as traumatic brain injury (TBI) and stroke. Founded in 2019 by world-renowned scientists with a track record of commercialization, the company addresses the critical need for early identification of life-threatening neurological events in settings ranging from home care to emergency medical services and battlefield environments. By providing continuous, non-invasive monitoring, MindRhythm aims to reduce diagnostic delays and improve patient outcomes across the care continuum. The company's platform leverages advanced signal processing and AI to detect subtle physiological changes indicative of neurological compromise. While specific funding and revenue details are not publicly disclosed, MindRhythm has demonstrated potential to transform neurocritical care by enabling earlier intervention. Its technology could reduce reliance on expensive imaging and specialist assessment, making neurological monitoring more accessible. The company's expertise in both neuroscience and device commercialization positions it well for regulatory milestones and strategic partnerships. As it progresses toward clinical validation and market entry, MindRhythm represents an innovative solution in the growing digital health and neurology markets.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for flagship neurodiagnostic device70% success
• Q2 2026Publication of pivotal clinical study results in peer-reviewed journal60% success
• Q4 2026Series A funding round led by strategic healthcare investors50% success